These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 25149706)
1. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. Yoo C; Ryu MH; Na YS; Ryoo BY; Park SR; Kang YK Ann Oncol; 2014 Nov; 25(11):2272-2277. PubMed ID: 25149706 [TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610 [TBL] [Abstract][Full Text] [Related]
3. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195 [TBL] [Abstract][Full Text] [Related]
4. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169 [TBL] [Abstract][Full Text] [Related]
6. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor. Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Oncology; 2016; 90(2):112-7. PubMed ID: 26779618 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540 [TBL] [Abstract][Full Text] [Related]
8. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953 [TBL] [Abstract][Full Text] [Related]
9. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Joensuu H; Blay JY; Comandone A; Martin-Broto J; Fumagalli E; Grignani G; Del Muro XG; Adenis A; Valverde C; Pousa AL; Bouché O; Italiano A; Bauer S; Barone C; Weiss C; Crippa S; Camozzi M; Castellana R; Le Cesne A Br J Cancer; 2017 Oct; 117(9):1278-1285. PubMed ID: 28850565 [TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372 [TBL] [Abstract][Full Text] [Related]
11. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734 [TBL] [Abstract][Full Text] [Related]
12. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076 [TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022 [TBL] [Abstract][Full Text] [Related]
15. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500 [TBL] [Abstract][Full Text] [Related]
17. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688 [TBL] [Abstract][Full Text] [Related]
18. Current research and treatment for gastrointestinal stromal tumors. Lim KT; Tan KY World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140 [TBL] [Abstract][Full Text] [Related]
19. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]